CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 331,000 shares, a decrease of 42.2% from the January 31st total of 572,600 shares. Currently, 28.1% of the shares of the company are sold short. Based on an average daily trading volume, of 626,400 shares, the short-interest ratio is currently 0.5 days.

Insider Activity at CERo Therapeutics

In related news, major shareholder Bioventures Opportunities G. Yk sold 12,368 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.00, for a total transaction of $148,416.00. Following the completion of the transaction, the insider now owns 213,839 shares of the company’s stock, valued at $2,566,068. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 64,300 shares of company stock worth $529,409 over the last quarter. Insiders own 18.00% of the company’s stock.

Institutional Trading of CERo Therapeutics

A hedge fund recently raised its stake in CERo Therapeutics stock. ARCH Venture Management LLC grew its stake in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 550.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,393,561 shares of the company’s stock after purchasing an additional 7,949,265 shares during the period. CERo Therapeutics comprises approximately 0.2% of ARCH Venture Management LLC’s investment portfolio, making the stock its 9th largest holding. ARCH Venture Management LLC owned 626.24% of CERo Therapeutics worth $564,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 29.64% of the company’s stock.

CERo Therapeutics Stock Up 3.7 %

Shares of CERO opened at $1.67 on Friday. The business’s 50-day moving average is $3.03 and its two-hundred day moving average is $8.95. CERo Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $1,095.00.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.